Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (NYSE: MDT) is a Galway, Ireland-based healthcare technology company whose news flow reflects its broad activity in medical devices, diabetes technology, surgical robotics, and cardiovascular therapies. Company announcements frequently highlight regulatory milestones, clinical evidence, product launches, capital markets activity, and corporate governance developments that matter to investors and healthcare professionals following MDT stock.
Recent news has featured U.S. Food and Drug Administration clearances for key technologies, including the Hugo robotic-assisted surgery (RAS) system for urologic procedures and the MiniMed Go Smart Multiple Daily Injection (MDI) system, which connects the InPen smart insulin pen and the Instinct sensor made by Abbott through the MiniMed Go app. Medtronic has also reported on the broad U.S. commercial launch of the MiniMed 780G automated insulin delivery system integrated with the Instinct sensor, expanding its diabetes technology ecosystem.
Investors can also track Medtronic’s cardiovascular and hypertension-related developments, such as the final National Coverage Determination from the U.S. Centers for Medicare & Medicaid Services for the Symplicity Spyral renal denervation system, and updates on growth drivers like pulsed field ablation and other cardiovascular therapies discussed in earnings releases. Financial news includes quarterly earnings reports, guidance updates, dividend declarations, and details of senior notes offerings and redemptions.
This MDT news page aggregates coverage of topics including diabetes business developments (such as the planned MiniMed IPO registration), conference presentations, leadership and board changes, and major clinical or reimbursement milestones. Readers interested in Medtronic’s role in chronic disease management, minimally invasive surgery, and global healthcare technology can use this page to follow ongoing announcements and review the company’s evolving strategic priorities over time.
Medtronic plc (NYSE: MDT) announced its participation in the ADA 81st Scientific Sessions from June 25-29, 2021. The company will present seven data presentations, including insights on its InPen smart insulin pen and Extended Infusion Set. Key studies include the impact of InPen on glycemic outcomes and results from the EWIS pivotal trial. Additionally, Medtronic will host a product theater and offer on-demand learning sessions, showcasing advancements in diabetes management technology aimed at improving patient care and glucose control.
On June 19, 2021, Medtronic (NYSE:MDT) successfully performed the first patient procedure using its Hugo™ robotic-assisted surgery (RAS) system at Clínica Santa María in Santiago, Chile. This milestone initiates the global patient registry for the Hugo RAS system, aimed at collecting clinical data for regulatory submissions worldwide. The system promises to enhance surgical precision while minimizing invasiveness, ultimately leading to better patient outcomes. However, the Hugo RAS system is not yet approved in the U.S. or Europe, with regulatory timelines yet to be determined.
Medtronic plc (NYSE: MDT) announced FDA expanded approval for its Arctic Front™ Family of Cardiac Cryoablation Catheters as an initial rhythm control strategy for recurrent symptomatic paroxysmal atrial fibrillation. This is the first approval allowing cryoablation before antiarrhythmic drug therapy failure. Results from the STOP AF First study showed cryoablation significantly outperforms drug therapy in preventing arrhythmia recurrence. Nearly 60 million people are affected by atrial fibrillation globally, with this new option providing a safer, effective alternative to traditional treatments.
Medtronic plc (NYSE: MDT) has received FDA approval for its Vanta™ neurostimulator, a recharge-free implantable device with a lifespan of up to 11 years, nearly doubling that of competitive devices. It features AdaptiveStim™ technology, which adjusts to patient movement, offering personalized pain relief. The device is designed for broad MRI compatibility, crucial for the 82% of spinal cord stimulation patients requiring MRI scans within five years. The Vanta is 20% smaller than its predecessor and includes data insights via Snapshot™ reporting.
Medtronic plc (NYSE:MDT) announced the STROKE AF trial results showing the Reveal LINQ™ Insertable Cardiac Monitor (ICM) significantly outperformed standard care in detecting atrial fibrillation (AF) in stroke patients. The study involved 496 patients, revealing AF detection rates of 12.1% in the ICM group versus 1.8% in standard care. The findings underscore the importance of long-term monitoring for stroke prevention, as 78% of AF patients could have been missed with traditional monitoring. The results, published in JAMA, highlight the potential for ICMs to transform secondary stroke prevention practices.
Medtronic plc (NYSE:MDT) announced FDA approval and first implants of the SenSight™ Directional Lead System for Deep Brain Stimulation (DBS) therapy. This innovative system uniquely combines directionality with sensing abilities, allowing for precise treatment of movement disorders like Parkinson's disease. SenSight is designed to enhance patient comfort, enable personalized therapy, and provide valuable brain activity data. Following its initial U.S. implants at the University of Florida, a full U.S. launch is imminent. The product has also received CE Mark for Western Europe earlier this year.
Medtronic (NYSE:MDT) has received FDA clearance for its patient-specific UNiD™ Rods, enhancing the functionality of its CD Horizon™ Solera™ Voyager™ and Infinity™ OCT spinal systems. These rods, tailored using AI-driven pre-operative surgical plans, aim to reduce malalignment risks during spinal surgeries. The first successful surgery using the UNiD Rods was performed in Indianapolis, highlighting their potential to improve surgical precision and outcomes. Medtronic emphasizes the integration of AI, robotics, and personalized implants to revolutionize spine care.
Medtronic plc (NYSE:MDT) announced the cessation of the HVAD™ System distribution due to a rise in neurological adverse events and mortality rates compared to other devices. This decision affects approximately 4,000 existing patients. Medtronic is launching a support program for these patients and their caregivers while coordinating with global regulators. The financial impact is anticipated to be neutral to slightly accretive to fiscal year 2022 non-GAAP diluted EPS, despite the HVAD generating $141 million in FY 2021 revenue.
Medtronic plc (NYSE:MDT) announced positive real-world outcomes for its MiniMed™ 780G insulin pump system, evaluating 4,120 users across Europe. The system demonstrated a 76.2% average Time in Range and maintained 94% of users in Advanced Hybrid Closed Loop mode. A smaller cohort of 812 individuals showed a 12.1% increase in Time in Range and a 0.4% percentage drop in GMI after using the system. Available in 30 countries, it is currently under FDA review for U.S. approval.
Medtronic (NYSE:MDT) will virtually participate in the 14th International Conference on Advanced Technologies & Treatments for Diabetes from June 2-5, 2021. The company will present significant clinical data on its MiniMed™ 780G System and Continuous Glucose Monitoring Systems, showcasing cost-effectiveness and real-world outcomes. Key presentations include the performance of the MiniMed™ 780G system in pediatric and adult trials and the effectiveness of the Guardian™ Sensor (3) Continuous Glucose Monitoring System. Medtronic aims to enhance diabetes management through innovative technologies and remote patient support.